Clinical trial
Empagliflozin to Elderly and Obese Patients With Cardiovascular Disease (Empire Prevent: Metabolic): A Randomized Controlled Trial
NCT05042973 is registered in ClinicalTrials.gov with Jacob Moller as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Empagliflozin to Elderly and Obese Patients With Cardiovascular Disease (Empire Prevent: Metabolic): A Randomized Controlled Trial
- Lead sponsor
- Jacob Moller
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 2, 2021
- Completion date
- January 23, 2025
- Enrollment
- 165 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.